Globus Medical Q4 revenue rises 25.7% on Nevro acquisition

Globus Medical

24/02/2026 21:50

Overview

Musculoskeletal technology firm's Q4 revenue grew 25.7%, driven by Nevro acquisition

Adjusted EPS for Q4 beat analyst expectations

Company reaffirmed 2026 revenue guidance, updating EPS forecast

Outlook

Globus Medical reaffirms 2026 revenue guidance at $3.18 to $3.22 bln

Company updates 2026 non-GAAP EPS guidance to $4.40-$4.50

Result Drivers

NEVRO ACQUISITION - Nevro acquisition added $99.7 mln to Q4 sales, significantly boosting revenue

CORE SPINE GROWTH - Core spine franchise contributed to above-market top-line growth

ENABLING TECHNOLOGIES - Enabling Technologies grew 19% over Q4 2024, contributing to record-setting results

Company press release: ID:nGNX15m4zt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$1.28
$1.15 (14 Analysts)
Q4 EPS
$1.03
Q4 Net Income
$140.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Globus Medical Inc is $108.00, about 15.6% above its February 23 closing price of $93.40

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)